Browsing Tag
ABS-1230
3 posts
Jazz Pharmaceuticals closes $820m Actio Biosciences deal to deepen epilepsy pipeline
Jazz Pharmaceuticals buys Actio Biosciences for $820 million upfront, betting on ABS-1230 while early-stage clinical risk remains the key test.
Jazz Pharmaceuticals raises $1.1bn at 1.875% while repurchasing $225m of stock
Jazz Pharmaceuticals has priced $1.1 billion of 1.875% exchangeable notes due 2032, generating about $1.08 billion of net proceeds while concurrently repurchasing $225 million of shares.
Jazz Pharmaceuticals to acquire Actio Biosciences for up to $1.32bn in rare epilepsy expansion
Jazz Pharmaceuticals is committing $820 million upfront for Actio Biosciences and ABS-1230, placing a sizeable bet on a genetically targeted epilepsy therapy whose ongoing Phase 1b/2a study could potentially support a U.S. approval filing.